ATC Group: C04AD03 Pentoxifylline

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C04AD03 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C04 Peripheral vasodilators
3 C04A Peripheral vasodilators
4 C04AD Purine derivatives
5 C04AD03 Pentoxifylline

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 1 g
PAREN - Parenteral 0.3 g

Active ingredients in C04AD03

Active Ingredient Description
Pentoxifylline

Pentoxifylline has been shown to increase leukocyte deformability and to inhibit neutrophil adhesion and activation.

Related product monographs

Title Information Source Document Type  
TRENTAL 400 Modified release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

Brazil (BR)

Croatia (HR)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

Germany (DE)

Israel (IL)

Malta (MT)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Romania (RO)

Singapore (SG)

Spain (ES)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.